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Myostatin (MSTN), a member of the TGF-β superfamily, was initially identified as a primary 
negative regulator of embryonic and postnatal skeletal muscle development. The MSTN gene is 
highly conserved among different species. Mutation of the MSTN gene results in a dramatic 
increase in skeletal muscle mass in mice, cattle, and humans. To date, most research has focused 
on the inhibitory role of MSTN on skeletal muscle growth, including the MSTN signaling 
pathway, the underlying mechanism of MSTN function, and the antagonists of MSTN. In this 
study, we identified a new property of MSTN. The project had 3 primary aims: (1) to 
characterize MSTN as a fibrogenesis stimulator; (2) to investigate the relationship between 
MSTN and TGF-β1, and (3) to investigate the effect of decorin on MSTN. Our findings 
demonstrate that MSTN stimulates fibroblast proliferation and induces differentiation of 
fibroblasts into myofibroblasts in vitro. We also showed that MSTN knockout (MSTN-/-) mice 
develop significantly less fibrosis and exhibit better muscle regeneration than wild-type mice 2 
weeks after gastrocnemius muscle (GM) laceration in vivo. In addition, we showed that TGF-β1 
stimulates MSTN expression in C2C12 myoblasts and, conversely, that MSTN stimulates the 
secretion of TGF-β1 by C2C12 myoblasts in vitro. In vivo, MSTN injected into the GM 
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stimulates myofibers to transiently co-express MSTN and TGF-β1. Moreover, TGF-β1 and 
MSTN colocalized in the necrotic myofibers shortly after GM laceration. Finally, our results 
showed that decorin, a natural inhibitor of TGF-β1, blocks the effects of MSTN. After co-
incubating cells with decorin and MSTN, we found that decorin reversed the stimulatory effect 
that MSTN had on skeletal muscle-derived fibroblasts and blocked the inhibitory effect that 
MSTN had on myogenic cells. In vivo, the expression levels of decorin in regenerating muscle 
are related to MSTN levels. Immunohistochemistry revealed higher decorin expression in 
MSTN-/- regenerating skeletal muscle than in wild-type skeletal muscle. Our results suggest that 
the role of MSTN in injured skeletal muscle is more complex than initially defined: MSTN 
inhibits skeletal muscle growth. MSTN helps to regulate both extracellular matrix deposition in 
injured muscle and myogenesis. These findings have afforded us a better understanding of the 
role of MSTN in skeletal muscle healing and indicated that MSTN could be a viable 
pharmacologic target for antifibrogenesis therapy. 
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1.0  INTRODUCTION 
Skeletal muscle injuries are one of the most common injuries encountered in sports medicine. 
Despite their clinical significance, current treatments remain conservative and include rest, ice, 
compression, and elevation (RICE principle), non-steroid anti-inflammatory drugs (NSAIDs), 
therapeutic ultrasound, and hyperbaric oxygen. More and more evidence has shown that 
administration of NSAIDs delays inflammation and regeneration and increases fibrosis [1-5]. 
Neither therapeutic ultrasound nor hyperbaric oxygen therapy has had beneficial effects on the 
final outcome of muscle healing [6, 7]. Injured muscle can undergo regeneration spontaneously, 
but the ensuing formation of fibrous scar tissue often impedes efficient muscle regeneration, 
resulting in incomplete healing [8, 9]. As a result, previously injured muscle continues to show 
muscle atrophy or loss of function, including loss of muscle extensibility and strength. Therefore, 
the prevention of fibrosis is key effort to improve skeletal muscle healing.  
Transforming growth factor-β1 (TGF-β1) is a potent fibrogenic cytokine in many tissues 
and organs, including the lungs, kidneys, liver, heart, and skin [10-13]. To date, it has been 
widely accepted that TGF-β1 is also associated with fibrosis in skeletal muscle [14-16]. Elevated 
TGF-β1 levels are observed in dystrophic skeletal muscle and shortly after skeletal muscle injury 
[14-17]. Research has shown that elevated expression of TGF-β1 accounts for the initiation and 
maintenance of fibrosis in muscular dystrophies [14, 15]. TGF-β1 has been proven to effectively 
induce myofibroblastic differentiation of fibroblasts both in vitro and in vivo, the induction of 
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which is responsible for excessive accumulation of fibrous tissue [18, 19]. Members of our 
research group have shown that TGF-β1 plays a significant role in both the initiation of fibrosis 
and the inducement of myofibroblastic differentiation of myogenic cells in injured muscle [17, 
20]. The use of antifibrosis therapies such as TGF-β1 neutralizing antibody, interferon-gamma 
(IFN-γ), suramin, relaxin, or decorin can improve the healing of injured muscle both 
histologically and physiologically [21-25]; however, none of these approaches can completely 
prevent fibrosis, and the precise mechanisms of fibrosis remain unclear. It is likely that other 
molecules positively regulate fibrosis, and myostatin (MSTN), a recently identified member of 
the TGF-β superfamily, is a probable candidate.  
MSTN was initially identified as a potent negative regulator of muscle development [26], 
and is predominantly expressed in skeletal muscle. MSTN knockout (MSTN-/-) mice are 
characterized by a dramatic and widespread increase in skeletal muscle mass [26]. Studies using 
mdx mice, which model Duchenne muscular dystrophy (DMD), subjected to MSTN gene 
knockout (MSTN-/-/mdx mice) have shown not only better muscle regeneration but also 
decreased fibrosis in the MSTN-/-/mdx mice compared with mdx mice expressing the MSTN 
gene (MSTN+/+/mdx mice) [27]. These results strongly suggest that MSTN plays an important 
role in fibrosis in skeletal muscle. In this study, we further characterized MSTN as a fibrosis 
stimulator. First, we hypothesized that MSTN plays a role in fibrogenesis. Second, given the 
putative role of TGF-β1 in fibrosis formation, we hypothesized that MSTN is related to TGF-β1. 
 Third, we hypothesized that decorin, an antifibrosis agent, inhibits MSTN as it does TGF-β1.  
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2.0  LITERATURE REVIEW 
2.1 MUSCLE REPAIR 
Skeletal muscle injuries are some of the most common injuries treated in sports medicine and 
account for 10% to 55% of all injuries sustained by athletes [28-30]. Muscle injury and repair 
have been widely investigated. Muscle injuries occur after either direct trauma (e.g., rupture or 
laceration) or indirect trauma (e.g., excessive stress, contusion, or strain). Regardless of the type 
of injury, injured muscles undergo a sequential series of events during the tissue repair process. 
The healing process of injured skeletal muscle includes 3 phases: inflammatory response, muscle 
repair, and muscle remodeling [8, 9, 30, 31]. Immediately after injury, the inflammation process 
is initiated and is characterized by hematoma formation resulting from ruptured blood vessels 
within the muscle tissue. Simultaneously, the damaged muscle undergoes necrosis and 
degeneration as a result of the disintegration of the muscle membrane, which leads to the 
activation of intracellular autodegradative pathways by an influx of calcium and the cytotoxin 
secreted by invading neutrophils. Numerous inflammation cells also invade the injured site 
during this early phase. The repair phase begins with phagocytosis of damaged tissue. Normally 
quiescent satellite cells known as myogenic precursor cells are activated. During the removal of 
tissue debris, activated satellite cells withdraw from their self-renewal cycle, readily 
differentiate, and either fuse with each other to form multinucleated myotubes or fuse with pre-
existing myofibers [31-34] (Figure 2.1; Figure 2.2). In the meantime, extracellular matrix (ECM) 
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components are synthesized by fibroblasts and capillary ingrowth is initiated. During the 
remodeling phase, regenerating myofibers undergo maturation and scar tissue reorganizes, events 
that lead to functional recovery of the injured muscle [30]. During skeletal muscle healing, an 
appropriate amount of ECM must be present to serve as a scaffold for fusing myoblasts [33, 35] 
and for the transmission of loads across the tissue defect. However, muscle regeneration and the 
deposition of ECM are concomitant and competitive events. Excessive connective tissue can 
form a dense mechanical barrier [36] that interrupts the milieu that is necessary for myofiber 
growth and prevents regenerated muscle myofibers from growing and elongating. Fibrosis is 
characterized by an excessive number of abnormally active fibroblasts,  the excess accumulation 
of collagen, disorganized ultrastructural morphology of the connective tissue, and an abnormal 
proportion of matrix components [37]. As a result, injured muscles heal but exhibit loss of 
function, including muscle atrophy and decreased extensibility and strength.   
      Injured muscle exhibits active muscle regeneration before the formation of thick and 
extensive connective tissue [9, 32, 38]. However, many newly formed myofibers express not 
only desmin, a myogenic marker, but also vimentin, fibroblast marker. Some of the regenerating 
myofibers are TGF-β1 positive as soon as 3 days after injury [17]. With the development of 
fibrosis, the vimentin- or TGF-β1-positive regenerating myofibers become smaller and gradually 
disappear due to replacement by mononucleated fibrotic cells and scar tissue [17, 39]. 
    To improve the healing of injured muscle, researchers have administered growth 
factors that can promote muscle regeneration, including insulin-like growth factor-1 (IGF-1), 
basic-fibroblast growth factor (bFGF), and nerve growth factor (NGF), to injured skeletal muscle 
[39-42]. Treatment with such growth factors—particularly IGF-1—enhanced muscle 
regeneration and strength to some extent; however, fibrosis still predominated and prevented 
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complete recovery of the injured muscle. As a result, researchers developed an alternative 
approach that blocks the fibrosis cascade. Antifibrogenesis agents such as anti-TGF-β1 antibody, 
suramin, IFN-γ and decorin can greatly improve muscle healing after injury [22-25, 43-45]. 
These agents all block the TGF-β1 signaling pathway by different mechanisms.  
 
 
   SZ   RZ(NZ)   CZ   RZ(NZ)      SZ 
Figure 2.1 A diagram of an injured skeletal muscle 
(After injury, the resulting defect (central zone (CZ)) caused by contraction of disrupted 
myofibers is immediately filled by a hematoma. Subsequent necrosis extends along the damaged 
myofibers (necrosis zone (NZ)) from the injured site with respective to the severity of the 
damage. In contrast, the remaining myofibers survive the trauma (survival zone (SZ)). After 
removal of necrotic myofibers through phagocytosis, muscle regeneration occurs within what 
used to be the NZ (regeneration zone (RZ)). Simultaneously, recruited fibroblasts begin to 
deposit ECM in the CZ. The regenerating myofibers reach out of the persisting basal lamina of 
the original myofibers and penetrate the connective tissue within the CZ. However, condensed 
scar resulting from fibrosis prevents myofibers from lengthening and growing within the CZ 
[31].) 
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 Figure 2.2 Initiation of muscle regeneration 
(During the repair phase, macrophages enter degenerating myofibers and debride contractile 
filament bundles and other necrotic debris, leaving the original basal lamina (thick arrow) as a 
scaffold that aids in muscle regeneration. After removal of necrotic tissue, spindle-shaped 
myoblasts (thin arrow) migrate toward and stay beneath the preserved basal lamina, and then 
fuse to form multinucleated myofibers.[31]) 
2.2 TGF-BETA1 
Fibrosis always prevents full recovery of injured muscle [8, 46]. TGF-β1 plays a major role in 
the fibrogenesis associated with fibrotic diseases and observed in a variety of damaged tissues, 
including skeletal muscle [10-17]. After muscle injury, the injury site contains a high level of 
TGF-β1 [17].  Li et al. (2004) found that, after muscle injury, some newly regenerating 
myofibers express TGF-β1 protein. The TGF-β1-positive regenerated myofibers are gradually 
replaced by mononucleated cells and TGF-β1-positive scar tissue. Moreover, Li et al. showed 
that direct injection of TGF-β1 into skeletal muscle causes early TGF-β1 autocrine expression 
within myofibers and fibrosis 2 weeks after injection [17].  
Transplanted free vascular grafts often undergo disorder or failure partially due to fibrosis 
in the graft beds [47]. After transplantation of myocutaneous gracilis flaps from the groin to the 
neck region, daily anti-TGF-β1 antibody injections significantly suppressed expression of 
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endogenous TGF-β1, thereby leading to a reduction of fibrosis and improving the healing of the 
free flaps [45] . Other antifibrosis agents that interfere with different steps of TGF-β1 signaling 
cascades, including decorin, suramin, and IFN-γ, also greatly improve muscle healing after 
injury [22-25]. Decorin directly interacts with TGF-β1 and prevents TGF-β1 from binding to its 
receptors. Suramin, an inhibitor of growth factor receptor activation, competitively prevents 
TGF-β1 from binding to the growth factor receptor, and by doing so inhibits the fibrotic effects 
of TGF-β1 [24, 25]. IFN-γ negatively regulates the TGF-β1 signaling pathway by directly 
inhibiting TGF-β1-induced phosphorylation of Smad3 and its attendant cascades, and induces 
the expression of inhibitory Smad7, which interferes with the interaction between Smad2/3 and 
the TGF-β type I receptor, and the complex formation among phosphorylated Smad2/3 and 
Smad4, and thereby interrupt Smad signalling [48]. 
Not only does TGF-β1 stimulate fibrosis, it also exerts an inhibitory effect on myogenic 
differentiation of myoblasts, including the C2C12, L6, Sol 8, L6E9, C-2 and BC3H1 cell lines 
[49-51]. TGF-β1 also inhibits the proliferation and differentiation of muscle satellite cells[52]  In 
contrast with control cells, which formed multinucleated myotubes and myofibrils, TGF-β1-
treated satellite cells remained mononucleated and developed distinct networks of stress fibers. 
Similarly, MSTN strongly inhibits proliferation and differentiation of both myoblasts and 
myogenic satellite cells. 
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2.3 MYOSTATIN 
MSTN, a recently identified member of the TGF-β superfamily, is a potent negative regulator of 
muscle development [26] expressed almost exclusively expressed in skeletal muscle. MSTN 
knockout (MSTN-/-) mice are characterized by a dramatic and widespread increase in skeletal 
muscle mass [26]. Recombinant MSTN and overexpressed MSTN from C2C12 myoblasts 
carrying amplified copies of a MSTN expression construct can inhibit both proliferation and 
differentiation of C2C12 myoblasts in vitro [53-56]. MSTN inhibits C2C12 myoblast 
proliferation by up-regulating p21, a cyclin-dependent kinase (CDK) inhibitor and decreasing the 
level and activity of Cdk2 protein. As a result, C2C12 myoblasts treated by MSTN were arrested 
in the G0 phase of cycle[53, 54].  MyoD, Myf5, MRF4, and myogenin are transcription factors 
of the basic helix-loop-helix-family of myogenic regulatory factors (MRFs).  MRFs play genetic 
hierarchy roles in the skeletal muscle development. MyoD and Myf5 are responsible for the 
determination of the myogenic lineage whereas myogenin and MRF4 are involved in the 
regulation of the process of terminal differentiation [57]. MSTN decreases the expression of 
myoD, Myf5 and myogenin proteins during differentiation [55, 56]. Additionally, the detected 
myoD was in an inactivated (dephosphorylated) form [53].  
Similar to other members of the TGF-β superfamily, MSTN is synthesized as a precursor 
protein consisting of a signal sequence, an N-terminal propeptide domain, and a carboxyl 
terminal (C-terminal) domain [26]. Like the TGF-βs, MSTN contains nine cysteine residues in 
the C-terminal region that is responsible for the activity of MSTN. After secretion, a precursor 
protein of MSTN undergoes proteolytic cleavage processing, and the resulting C-terminal 
regions are capable of forming a dimer linked by a disulfide bond [26]. TGF-β1 and MSTN 
share some downstream steps in the signaling pathway. The signaling cascades of TGF-β 
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superfamily members are classified into activin/TGF-β and bone morphogenetic protein 
(BMP)/growth and differentiation factor (GDF) pathways [58-60]. In the former type of 
pathway, TGF-β, activin, and nodal-related ligands initially bind to type II receptors (TβRII and 
ActRII, respectively), which results in the formation of a complex containing 2 copies each of 
receptor II and receptor I (TβRI is known as activin receptor-like kinase (ALK): ALK5, ALK7, 
or ALK4). Activated type I receptors then induce the phosphorylation of Smad2 and/or Smad3, 
which further complex with Smad4. The complex of Smad2 and/or Smad3 and Smad4 
translocates into nucleus and thereby launch the transcription of Smad2/Smad3-dependent target 
genes. In contrast, BMP/GDF-like ligands bind to BMPRII or ActRII/IIB. The resulting complex 
induces phosphorylation of Smad1, Smad5, and/or Smad8, which also form complex with 
Smad4, and thereby regulates the expression of BMP target genes. Recent studies have shown 
that, like TGF-β1 signaling, MSTN signal propagation requires the participation of Smad2 and 
Smad3 rather than the participation of Smad1, Smad5, and Smad8 [61-63]. The binding of 
MSTN to ActRIIB recruits a type I receptor—either activin receptor 4 (ALK4 or ActRIB) or 
ALK5 (TβRI)—that then phosphorylates Smad2 and Smad3 and activates a TGF-β-like signal 
transduction pathway[61-63]. MSTN signaling cascades are negatively regulated by the 
inhibitory Smad7 rather than by Smad6 [62].  
Currently, research on MSTN mostly focuses on regulation of MSTN during skeletal 
muscle development. The potential role of MSTN in fibrogenesis has not been clarified. The 
dystrophin-deficient mdx mouse is commonly used as an animal model for DMD. Skeletal 
muscle from both mdx mice and individuals with DMD undergoes repetitive muscle 
degeneration and regeneration. The increased expression of TGF-β1 in dystrophic skeletal 
muscle is the primary contributor to fibrosis in muscular dystrophies [15]. Nine-month-old mdx 
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mice exhibit extensive fibrosis in their diaphragms. However, 9-month-old mdx mice lacking 
MSTN expression (MSTN-/-/mdx) exhibit significantly less fibrosis [27]. These results suggest 
that MSTN might be a fibrosis-related protein. The role of MSTN in fibrosis warrants further 
investigatation. Decorin has been shown to inhibit fibrosis in muscle. However, its inhibition of 
fibrosis is typically attributed to its blocking of TGF-β1. Our project examined whether decorin 
also inhibits MSTN. 
2.4 DECORIN 
Decorin, a small chondroitin-dermatan sulphate leucine-rich proteoglycan, is composed of a core 
protein and a single glycosaminoglycan chain [64, 65]. Three different small proteoglycan with 
leucine-rich repeats (i.e., decorin, biglycan, and fibromodulin) are able to bind and inactivate 
TGF-β1 [66]. Decorin has been studied widely, primarily because it is ubiquitous in the ECM 
and has antifibrogenic properties.  
Decorin’s core protein can bind to TGF-β1 and inhibit its activity [67, 68]. TGF-β1 
stimulates the growth of Chinese hamster ovary (CHO) cells. However, the overexpression of 
decorin resulting from transfection of decorin cDNA suppresses the proliferation of transfected 
CHO cells compared with non-transfected CHO cells [64, 67]. Further experiments revealed 
complexes of decorin and TGF-β1. The activity of TGF-β1 dimer was restored after it was 
released from the complex [67]. TGF-β induces synthesis of decorin in many cell types, which 
suggests that decorin may play a role in the negative feedback of TGF-β [24, 67]. Decorin has 
been used as an antifibrogenic agent in lung, liver, kidney, and muscle tissue because of its 
biologic binding and neutralizing of TGF-β1 [21, 22, 37, 64, 69, 70]. Members in our research 
 10 
group found that decorin can improve skeletal muscle healing by promoting muscle regeneration 
and decreasing fibrosis [21, 22]. In order to further investigate the mechanisms by which decorin 
exerts beneficial effects on skeletal muscle healing, the effect of decrin on MSTN was examined 
in this study. 
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3.0  SPECIFIC AIMS 
Skeletal muscle is capable of regenerating after injury. However, severe muscle injuries often 
result in incomplete recovery because initial muscle regeneration is interrupted and gradually 
supplanted by increasing fibrosis. TGF-β1 is a putative stimulator of fibrogenesis in a variety of 
tissues and organs. Although many studies have shown a strong correlation between elevated 
TGF-β1 levels and muscle fibrosis, the underlying mechanism remains unclear. Other molecules 
may also play a role in muscle fibrosis. MSTN, the newly identified member of the TGF-β 
superfamily, also might contribute to fibrosis. In contrast to the ubiquitous distribution of TGF-
β1, MSTN is almost exclusively expressed in skeletal muscle. The absence of MSTN causes a 
reduction in fibrosis in the skeletal muscle of mdx mice [71], a finding that suggests that MSTN 
might also play a role in muscle fibrosis. Because of the crucial role of TGF-β1 in fibrogenesis, 
an effect of MSTN on fibrosis likely involves an interaction with TGF-β1. Decorin, a well-
known antifibrogenic agent, improves muscle healing by inhibiting fibrosis. Although 
researchers believe that decorin inhibits fibrosis by binding with TGF-β1, it is unknown whether 
decorin can block the biologic activity of MSTN. Therefore, the overall objectives of this project 
were to investigate (1) the fibrogenic effects of MSTN, (2) the potential relationship between 
MSTN and TGF-β1, and (3) the potential inhibitory effect of decorin on MSTN (Figure 3.1).  
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Specific Aims 
Decorin 
Myostatin 
TGF−β1   
Scar tissue Δ  
3) 1) 
2) 
(-) (+) 
 
Figure 3.1 Specific aims indicated by orange arrows: Determine if (1) myostatin is a 
stimulator of fibrogenesis; (2) TGF-β1 is related to myostatin; and (3) decorin inhibits 
myostatin 
3.1 SPECIFIC AIM I 
The first aim of this study was to determine the effects of MSTN on fibroblasts in vitro and 
whether MSTN deficiency causes less scar tissue formation and better regeneration during 
muscle healing. During the repair phase of muscle healing, fibroblasts migrate to the wound site, 
propagate, differentiate into myofibroblasts, and synthesize components of ECM to fill the tissue 
defect. Excessive activity of myofibroblasts is responsible for abnormal accumulation of ECM. 
Alpha-smooth muscle actin (α-SMA), the actin isoform originally found in contractile vascular 
smooth muscle cells, is the most reliable marker of myofibroblasts identified to date. Therefore, 
if MSTN plays a role in fibrogenesis, it is likely that MSTN stimulates proliferation of 
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fibroblasts and its myofibroblastic differentiation in vitro and that the lack of MSTN  directly 
leads to less fibrosis in injured muscle in vivo.  
Hypothesis 1a: Myostatin stimulates the proliferation of fibroblasts and induces α- SMA  
                         synthesis in fibroblasts in vitro.  
Hypothesis 1b: Lack of myostatin (MSTN-/-) results in improved healing after skeletal  
                         Muscle laceration in vivo. 
3.2 SPECIFIC AIM II 
The second aim of this study is to investigate the potential relationship between TGF-β1 and 
MSTN. TGF-β1 plays a crucial role in fibrogenesis in various tissues [11-13, 69]. Although 
elevated TGF-β1 levels are associated with fibrosis in dystrophic muscle, loss of MSTN reduces 
fibrosis in mdx mice [27]. TGF-β1 may interact with MSTN and thus cause more fibrosis than 
does TGF-β1 alone. Moreover, both TGF-β1 and MSTN are members of the TGF-β superfamily. 
TGF-β1 and MSTN have similar biologic effects on fibroblasts and myoblasts. We and others 
have shown that TGF-β1 and MSTN inhibit the proliferation and myogenic differentiation of 
myoblasts and stimulate the proliferation and myofibroblastic differentiation of fibroblasts. 
However, the exact relationship between TGF-β1 and MSTN remains unclear. 
Hypothesis 2a: TGF-β1 induces C2C12 myoblasts to express myostatin, and myostatin  
                         increases TGF-β1 synthesis in C2C12 myoblasts in vitro.  
Hypothesis 2b: Injection of MSTN into skeletal muscle induces TGF-β1 expression in  
                         myofibers in vivo. 
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3.3 SPECIFIC AIM III 
The third aim of this study is to examine whether decorin can block the biologic activity of 
MSTN as it does the biologic activity of TGF-β1. Decorin is a small proteoglycan composed of a 
core protein and a single glycosaminoglycan. The core protein of decorin, which contains 10 
repeats of a 24-amino acid leucine-rich sequence, is responsible for the ability of decorin to bind 
with TGF-β [67, 68]. Like other TGF-β family members, the bioactive molecule of MSTN is a 
homodimer of two proteolyticly processed C-terminal fragments linked by a disulfide bond [26].  
Although there is low sequence homology in the C-terminal region between other members of 
the TGF-β family and MSTN (34%), the C-terminal region of MSTN, like that of TGF-βs, 
contains 9 cysteine residues with a conserved pattern. Because of the similarities between TGF-
β1 and MSTN in term of structural and bioactive properties, we specifically investigated whether 
decorin could block MSTN-induced protein expression in fibroblasts, inhibit the stimulation 
effect of MSTN on fibroblast proliferation, and prevent the inhibitory effect of MSTN on 
myoblasts in vitro and possible alteration of decorin expression in injured MSTN-/- muscle 
compared to wide-type (WT) muscle in vivo.  
           Hypothesis 3a: Decorin inhibits the effect of MSTN on fibroblasts and myoblasts in vitro. 
           Hypothesis 3b: Decorin expression varies between the injured skeletal muscles of  
                        MSTN-/- and WT mice. 
The results of this thesis project clarified that MSTN is a stimulator in fibrogenesis, and 
revealed a relationship between TGF-β1 and MSTN, and showed that decorin inhibits MSTN. 
TGF-β1, MSTN, and decorin are important for muscle healing. These findings should lead to a 
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better understanding of the cellular and molecular mechanisms of fibrosis in skeletal muscle and 
could help in the development of strategies to prevent fibrous tissue formation. 
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4.0  THE ROLE OF MYOSTATIN IN INJURED MUSCLE 
4.1 ABSTRACT 
Although MSTN is a primary negative regulator of muscle growth, some evidence has suggested 
that it may be involved in fibrosis in skeletal muscle. The purpose of this study was to explore 
the fibrogenic effects of MSTN. We first investigated its effect on fibroblasts, and then we used 
MSTN-/- mice to investigate whether loss of MSTN improves muscle healing by enhancing 
regeneration and reducing fibrosis. We found that MSTN stimulated proliferation of both 
muscle-derived fibroblasts and NIH/3T3 fibroblasts. Moreover, MSTN induced synthesis of α-
SMA in fibroblasts, which is a marker of myofibroblasts. Our in vivo results showed elevated 
MSTN expression in injured skeletal muscle of WT mice. A separate experiment showed that a 
lack of MSTN led to improved regeneration and decreased fibrosis 2 weeks after muscle 
laceration. Collectively, these results suggest that MSTN is associated with fibrosis in skeletal 
muscle. This finding sheds new light on the underlying mechanism of skeletal muscle fibrosis. 
4.2 INTRODUCTION 
Skeletal muscle injuries are the most common injuries encountered in sports medicine. Muscle 
injuries can heal spontaneously through regeneration, but fibrosis impedes this process and 
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results in incomplete functional recovery. We have demonstrated that TGF-β1 plays a significant 
role in muscle fibrosis formation through the initiation of fibrosis and the inducement of 
myofibroblastic differentiation of myogenic cells in injured muscle [1]. Therapies based on 
neutralizing TGF-β1 can greatly decrease fibrosis. Some evidence also has shown that, in the 
absence of MSTN, mdx mice exhibit less severe and extensive fibrosis than observed in 
MSTN+/+/mdx mice [27]. Therefore, MSTN may also play a role in muscle fibrosis. The role of 
MSTN in fibrogenesis is especially important to investigate to further understand the underlying 
mechanism of fibrosis and to improve the pharmacologic strategy of antifibrogenesis therapy. 
This study consisted of 2 parts. The first objective was to examine the effects of MSTN on 
fibroblasts, the cells responsible for ECM deposition during tissue healing. The second objective 
was to examine whether the absence of MSTN in healing muscle reduces fibrosis.   
4.3 MATERIALS AND METHODS 
4.3.1 Fibroblast isolation 
The preplate technique was used to isolate fibroblasts from muscle [72] and enrich them by 
taking advantage of the fact that they adhere to collagen-coated flasks faster than do myoblasts. 
The gastrocnimus muscles (GMs) were removed from 4-week-old C57BL/6J mice and minced 
into coarse slurry. The muscle slurry was digested with 0.2% collagenase-type XI for 1 h, 
dispase (grade II, 240 ml) for 30 min, and 0.1% trypsin for an additional 30 min at 37oC. The 
muscle cell extract was resuspended in proliferation medium (PM) consisting of Dulbecco’s 
modified Eagle’s medium (DMEM; Invitrogen., Carlsbad, CA), 10% horse serum (HS; 
 18 
Invitrogen., Carlsbad, CA), 10% fetal bovine serum (FBS; Invitrogen., Carlsbad, CA), 1% 
penicillin/streptomycin (P/S; Invitrogen., Carlsbad, CA), and 0.5% chicken embryo extract 
(CEE, Accurate Chemical & Scientific Corporation, Westbury NY), and was preplated on 
collagen-coated flasks. A population of preplated (PP1) fibroblast that attached within the first 2 
h was collected and used as skeletal muscle-derived fibroblasts. PP1 fibroblasts were maintained 
in DMEM with additions of 10% FBS and 1% P/S until use.  
4.3.2 Protein expression and proliferation assay 
NIH/3T3 fibroblasts were purchased from the American Type Culture Collection (ATCC) 
(Rockville, MD) and cultured in the same conditions as the PP1 fibroblasts. NIH/3T3 fibroblasts 
or PP1 fibroblasts were plated onto collagen-coated 96-well plates for analysis of cell 
proliferation and onto 6-well plates for evaluation of α-SMA expression. Following overnight 
attachment, normal medium was removed and replaced with serum-free medium supplemented 
with serum replacement (Sigma, St. Louis, MO) and varying concentrations of recombinant 
human MSTN (0, 100, 500, or 1000 ng/mL for proliferation assay; 0, 100, or 500 ng/mL for 
western blot; Lenico Technologies, Inc. St. Louis, MO). After an additional incubation for 48 h, 
a MTT (3-[4, 5-dimethylthiazol-2-y]-2, 5-diphenyl tetrazolium bromid) cell proliferation assay 
kit (Roche Diagnostics, Germany) was used as suggested by the manufacturer to measure cell 
proliferation; western blot was used to examine α-SMA expression.  
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4.3.3 Western blot 
After being cultured, the cells were lysed with T-PER® Tissue Protein Extraction Reagent 
(Pierce, Rockford, IL). BCA Protein assay kit (Pierce, Rockford, IL) was used to measure 
protein concentration of samples, following instructions from manufacture. Protein samples were 
mixed with ImmunoPure Land Marker Reducing Sample beffer (Pierce, Rockford, IL). Equal 
amounts of protein were loaded into and separated by 10% sodium dodecyl sulfate (SDS) 
polyacrylamide electrophoresis gel. Blotting to nitrocellulose membranes was performed under 
standard conditions. All primary antibodies, including mouse anti-α-SMA (1:1000; Sigma., St. 
Louis, MO) and mouse anti-β-actin (1:8000; Sigma, St. Louis, MO) were incubated with the 
membrane overnight at 4oCCC. β-actin expression was used as a control to ensure loading of equal 
amounts of protein, The horseradish peroxidase-conjugated secondary antibody anti-mouse IgG 
(1:10,000; Pierce, Rockford, IL) was incubated with blots for 1 h at room temperature; 
SuperSignal West Pico Chemiluminescent substrate (Pierce, Rockford, IL) was used for 
developing the blots. Target bands were visualized on Kodak Biomax MR Film (Sigma, St. 
Louis, MO).   
4.3.4 Animal experiments 
4.3.4.1 MSTN expression in the skeletal muscle after injury 
All experimental protocols were approved by the Children’s Hospital of Pittsburgh IACUC. 
In this study, 18 C57BL/6J WT mice (7 to 8 weeks of age, Jackson Laboratory, Bar Harbor, ME) 
were used to investigate MSTN expression after muscle injury. All mice underwent bilateral GM 
laceration as previously described [22-24]. The mice were anesthetized with isofluorane 
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delivered by an anesthetic machine.  A surgical blade (no. 11; SteriSharps, Mansfield, MA) was 
used to lacerate the GM of each leg at the largest diameter through the lateral 50% of the muscle 
width and 100% of the muscle thickness. After laceration, the skin was closed with black silk 4-0 
suture (Ethicon. Someville, NJ). After GM laceration, 3 mice were euthanized and GMs were 
harvested at each time point (1, 3, 5, 7, 10, and 21 days). The muscles were isolated, removed, 
snap frozen in 2-methylbutane precooled in liquid nitrogen, and stored at –80oC. 
Immunohistochemistry then was performed. 
4.3.4.2 Comparison of skeletal muscle healing between MSTN-/- mice and WT mice 
C57BL/6J WT and MSTN knockout (MSTN-/-) mice with 6J background (7 to 8 weeks of age) 
were used in this study. The breeders of MSTN-/- mice were a gift from Dr. Se-Jin Lee at Johns 
Hopkins University. All MSTN-/- mice used in experiments were offspring of MSTN-/- 
homozygotes. Polymerase chain reaction (PCR) was used to confirm the genotype of the MSTN-
/- mice. Reverse transcription-polymerase chain reaction (RT-PCR) was used to confirm the lack 
of MSTN gene transcription in randomly selected MSTN-/- mice. Primer sequences included the 
following: WT 220bp, upper 5’-AGA AGT CAA GGT GAC AGA CAC AC-3’, lower 5’-GGT 
GCA CAA GAT GAG TAT GCG-G-3’; MSTN-/- 332 bp, upper 5’-GGA TCG GCC ATT GAA 
CAA GAT G-3’, lower 5’-GAG CAA GGT GAG ATG ACA GGA G-3’), MSTN 345 bp, 
U84005. upper: 5’-GCA CTG GTA TTT GGC AGA GTA-3’, lower: 5’-CAC ACT CTC CAG 
AGC AGT AAT-3’. Phenotype was also confirmed by comparison of the skeletal muscle mass 
of MSTN-/- mice with that of their WT counterparts. In each group, 6 WT or 6 MSTN-/- mice 
were used and underwent bilateral GM laceration as previously described [22-24]. Mice were 
sacrificed and GMs were harvested 2 weeks after surgery. The harvested muscles were processed 
as described in section 4.3.4.1. Histology and immunohistochemistry then were performed. After 
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Masson’s Trichrome staining, Northern Eclipse software (Empix Imaging, Inc.) was used to 
measure the areas of fibrotic tissue in the injured sites. After anti-collagen type IV 
immunostaining was performed to identify the basal lamina of myofibers, Northern Eclipse 
software was used to measure the regeneration capacity in terms of the diameter of regenerating 
myofibers. Student’s t-test was used to determine significance (P<0.05). 
4.3.5 Immuohistochemistry 
GMs were frozen as described above and sectioned at 10-μm thickness. Immunohistochemical 
analysis was performed to detect collagen type IV and MSTN expression. The sections were 
fixed in 4% formalin for 5 min and then were washed in phosphate buffered solution (PBS) twice 
for 10 min each time. The sections were blocked with 10% HS (Vector Laboratory, Burlingame, 
CA) for 1 h. Then the primary antibody rabbit anti-collagen type IV (1:200; BD PharMingen. 
San Diego, CA) or rabbit anti-MSTN (1:100; Chemicon, Temecula, CA) was applied in 2% HS 
and the sections were incubated overnight at 4oC. After being washed in PBS 3 more times (10 
min per time), the sections were incubated with the secondary antibody, goat anti-rabbit IgG 
conjugated with 555 (diluted 1:300 with 2% HS, Molecular Probes-Invitrogen, Carlsbad, CA), 
for 1 h. Hoechst (Sigma, St. Louis, MO) was used to stain nuclei. 
4.3.6 Masson’s Trichrome staining 
Masson’s Trichrome staining was carried out as previously described [3, 17, 23, 44]. Frozen 
sections were incubated in preheated Bouin’s solution for 30 min. After a quick rinse with 
deionized water, the sections were sequentially stained in hematoxylin and Biebrich’s Scarlet 
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Acid Fuchsin solution for 15 min. After incubation with phosphotingstic/phosphomolybdic acid, 
the sections were directly transferred into Aniline blue solution where they remained for an 
additional 15 min. The sections then were dehydrated through treatment with 70%, 80%, 90%, 
and 100% ethanol. This procedure stains nuclei black, muscle red, and collagen blue.  
4.3.7 Quantification of diameters of regenerated myofibers and fibrosis 
To quantify the extent of muscle regeneration, frozen sections were immunohistochemically 
stained with collagen type IV to reveal the basal lamina of myofibers. Regenerating myofibers in 
3 nonadjacent sections of each muscle were photographed, and Northern Eclipse software was 
used to automatically measure the minimal diameters of myofibers. After Masson’s Trichrome 
staining, fibrous scar tissue was measured in terms of the ratio of the collagenous area to the total 
area of the muscle cross section. Detailed protocols are provided seen in Appendix A and B. 
4.3.8 Statistical Analysis 
All results in the thesis are shown as the mean ± standard deviation (SD). Differences with P < 
0.05 were accepted as statistically significant. Differences between control and treated groups 
were tested with Student’s t-test. Comparisons among 3 groups were analyzed by one-way 
analysis of variance (ANOVA) followed by Tukey's multiple comparison test to detect 
differences between groups. 
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4.4 RESULTS 
4.4.1 The effect of MSTN on protein expression and proliferation of fibroblasts 
We used immunocytochemistry to identify both desmin (a myogenic marker) and vimentin (a 
fibroblastic marker) expression to characterize muscle-derived fibroblasts (data not shown). 
MTT tests were performed to measure cell proliferation. Metabolic active cells cleave the yellow 
tetrazolium salt, which produces purple formazan crystals that are soluble in proper 
solubilization solution [73, 74].  Cell proliferation then is determined by measurement of the 
absorbance of formazan salt at 570 nm, which is correlated with the number of viable cells. Our 
results show that after 48 h of incubation, MSTN significantly stimulated NIH/3T3 fibroblasts 
and PP1 fibroblasts to proliferate in a dose-dependent manner from concentrations of 100 ng/mL 
to 1000 ng/mL (Figure 4.1, Figure 4.2). This result is similar to those generated previously by 
our group showing that TGF-β1 significantly promotes the proliferation of PP1 fibroblasts [22].   
Numerous studies have substantiated the notion that wound healing involves the transient 
presence of myofibroblasts that are responsible for wound contraction and most ECM deposition 
[75-77]. However, the excessive activity of myofibroblasts results in abnormal accumulation of 
ECM [78, 79]. Alpha-SMA, is the most reliable marker of myofibroblasts identified to date. 
Western blot analysis in our study revealed that MSTN at concentrations of 100 and 500 ng/mL 
increased α-SMA expression in NIH/3T3 fibroblasts (Figure 4.3).  
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 Figure 4.1 Myostatin stimulates proliferation of NIH/3T3 fibroblasts (** P<0.01) 
 
 
 
Figure 4.2 Myostatin stimulates proliferation of muscle-derived fibroblasts (** P<0.01) 
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Figure 4.3 Myostatin stimulates α-SMA expression in NIH/3T3 fibroblasts 
4.4.2 MSTN expression in injured skeletal muscle 
To study MSTN expression after muscle injury, we used a mouse model of GM laceration. After 
laceration, we tracked the expression profile of MSTN at different time points (1 to 3 days; 5 to 
10 days, and 21 days after injury) selected to roughly correspond with the degenerative, repair, 
and remodeling phases of muscle healing, respectively. As indicated in a previous report [80], 
immunostaining for MSTN revealed high levels of MSTN protein within necrotic myofibers 
infiltrated with numerous neutrophils 1 day after injury (Figure 4.4-A1). However, we detected 
no positive signal in mononucleated cells. By day 3, numerous monocytes had infiltrated the 
injured site and had begun removing damaged tissue. Some remnants of necrotic myofibers 
remained highly MSTN positive at this time point (Figure 4.4-B1). We also observed a few 
positively stained mononuclear cells distributed throughout the injury site. On day 5, we 
observed many newly regenerating myotubes: we saw relatively faint MSTN expression in the 
cytoplasm of regenerating myofiber and intense staining in the nuclei of mononucleated cells and 
of regenerating myofibers (identified by their centralized nuclei) (Figure 4.4-A2, B2). The 
MSTN-positive signal visible initially in the cytoplasm of regenerating myofibers disappears 
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with maturation of the regenerating myofiber (Figure 4.4-A3, B3), whereas the nuclei of 
regenerated myofibers remain MSTN positive.  
 
Figure 4.4 Myostatin expression (red fluorescence) in skeletal muscle after laceration 
(White arrows in A1and B1 indicate necrotic myofibers with elevated MSTN expression. White 
arrows in A2 and B2 show the cytoplasmic expression of MSTN in regenerated myofibers. 
White arrowheads show a positive MSTN signal in the nuclei of regenerated myofibers. Yellow 
arrowheads identify the outlines of regenerated myofibers.) 
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4.4.3 Improved healing after GM laceration in MSTN-/- mice compared to WT mice 
To determine whether lack of MSTN leads to better muscle healing after GM laceration, we 
measured muscle regeneration and fibrosis in the injured sites of MSTN-/- and WT mice 2 and 4 
weeks after laceration. Two weeks after GM laceration, we observed improved muscle healing in 
MSTN-/- mice, as evidenced by enhanced muscle regeneration (Figure 4.5; Figure 4.6) and 
reduced fibrosis (Figure 4.7; Figure 4.8) in the MSTN-/- mice compared with WT mice. The 
regenerating myofibers were identifiable by their centralized nuclei (Figure 4.5). As shown in 
Figure 4.6, the regenerating myofibers (mean diameter = 36.11 ± 7.32 µm) in the muscles of the 
MSTN-/- mice were significantly larger than those in the regenerating muscles of the WT mice 
(mean diameter = 25.98 ± 7.04 µm). Masson’s Trichrome staining shows myfibers in red, 
collagen in blue, and nuclei in black (Figure 4.7) revealing a lot of collagenous tissue deposition 
in injured muscle of WT mice. Quantification indicated by the ration of collagenous tissue area 
to area of entire muscle section shows significantly less scar tissue in the injured GMs of MSTN-
/- mice than in those of WT mice (Figure 4.8).  
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 Figure 4.5 Regenerated muscle from MSTN-/- mice contains regenerated myofibers with 
larger diameters than those of regenerating myofibers in WT mice 2 weeks after laceration 
 
 
Figure 4.6 The diameter of regenerated myofibers in MSTN-/- mice is significantly larger 
than the diameter of regenerating myofibers in WT mice 2 weeks after muscle injury 
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 Figure 4.7 Injured muscles from MSTN-/- mice contain less collagenous tissue than do 
injured muscles in WT Mice 
 
Figure 4.8 Significantly less collagenous tissue deposition in injured MSTN-/- mice than in 
injured WT mice 
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4.5 DISCUSSION 
We observed kinetic MSTN expression during the healing of lacerated skeletal muscle. Our 
results show MSTN expression in the cytoplasm of necrotic myofibers after muscle injury but no 
MSTN signal in the sarcoplasm of normal skeletal muscle. We also detected faint MSTN 
expression in the cytoplasm and strong MSTN expression in the nuclei of regenerating 
myofibers. The enhanced MSTN expression and its nuclear location in regenerating myofibers 
observed in our study are consistent with the results of previous studies. Research has shown 
upregulated in vitro MSTN expression in myotubes compared with C2C12 myoblasts [81-83]. 
MSTN also is expressed in satellite cells and adult myoblasts. Using dual-immunocytochemical 
staining, Artaza et al. [81] revealed MSTN protein in most of the nuclei of myosin heavy chain 
II-positive multinucleated myotubes. Western blot analysis revealed the exclusive expression of 
MSTN in isolated nuclear portions of myotubes rather than in cytoplasmic portions [81]. 
Dexamethasone can upregulate MSTN expression in the nuclei of myotubes, and high 
concentrations of dexamethasone promote the extension of MSTN expression to the cytoplasm 
[81]. In our study, we observed extensive MSTN expression within newly regenerating 
myofibers 5 days after laceration. On day 10, the MSTN protein was not visible in the cytoplasm 
of most regenerated myofibers. This suggests that the cytoplasmic expression of MSTN is related 
to the maturation of regenerated myofibers and the progression of muscle repair. The constantly 
elevated levels of MSTN protein in the nuclei of regenerated myofibers suggest that MSTN plays 
a role in transcriptional regulation of muscle development. As we described previously, the 
MSTN-Smad signal transduction pathway requires active MSTN molecules to bind to 
transmembrane activin receptor IIB.  Thus, if MSTN act as a transcription factor, it probably 
signals through a non-Smad signal transduction pathway in that case. 
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The results of this study show that MSTN stimulates the proliferation and 
myofibroblastic differentiation of fibroblasts in vitro. The absence of MSTN improves muscle 
healing by enhancing muscle regeneration and reducing fibrosis. Below we discuss the possible 
beneficial effects of MSTN deficiency on muscle healing during the 3 phases of muscle healing 
(i.e., inflammation, repair, and remodeling). Possible mechanisms by which the absence of 
MSTN might improve muscle healing include the following: (1) Accelerated inflammatory 
response; (2) Enhanced muscle regeneration; (3) Reduced deposition of connective tissue; (4) 
Enhanced maturation of regenerated myofibers; and (5) Increased degradation of ECM 
components.  
4.5.1 Inflammation 
 In response to various types of muscle injury, numerous neutrophils immediately infiltrate 
damaged tissues. As neutrophils undergo rapid degranulation and disappear, macrophages 
quickly populate and predominate at the wound site. Although macrophages damage myofibers 
by releasing free radical oxidants, appropriate inflammation has a beneficial influence on muscle 
healing. Macrophages scavenge damaged tissue to remove debris that could hinder muscle 
regeneration. A variety of growth factors and cytokines secreted by macrophages (e.g., platelet-
derived growth factor (PDGF), TGF-β, bFGF, and leukemia inhibitory factor (LIF)) have either 
chemotactic effects or mitogenic effects or both types of effect on muscle precursor cells and 
thereby accelerate muscle regeneration [84-88]. Necrotic tissue impedes effective muscle 
regeneration [89]. Some observations indicate that a slower rate of muscle regeneration in older 
animals or some animal strains correlates with the  slower rates of removal of muscle debris by 
phagocyotosis [89, 90]. Recently, Shen et al. found that NS-398, a cyclooxygenase-2-specific 
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inhibitor, reduces macrophage recruitment within 24 hours after injury, which delays skeletal 
muscle healing by decreasing muscle regeneration and reducing fibrosis [3]. The elevated TGF-
β1 and MSTN expression in NS-398-treated injured muscle could be responsible for the 
increased fibrosis observed in that muscle in comparison with nontreated injured muscle.  
Our results show greatly elevated expression of MSTN in the cytoplasm of necrotic 
myofibers 1 day after laceration. High levels of the MSTN protein remain in necrotic myofibers 
until removal of the necrotic debris.  Our finding parallels those of Kirk et al. (2000), who 
reported high levels of MSTN protein within nectrotic fibers in the muscles of rats damaged by 
notexin, a mytoxin [80]. A separate study used western blot analysis to verify the upregulation of 
MSTN protein at early time points in rat skeletal muscles injured by notexinin [91]. The transient 
increase of MSTN in necrotic myofibers may regulate muscle regeneration processes by 
influencing the early events of phagocytosis during inflammation.  
Interestingly, research has shown that MSTN interferes with the chemotaxis of 
macrophages in vitro.  The addition of recombinant MSTN significantly reduces the migration of 
macrophages and myoblasts towards chemoattractants in vitro [71]. Compared with WT mice, 
MSTN-/- mice show elevated recruitment of macrophages and myoblasts and an accelerated 
inflammatory response after muscle injury [71]. Necrotic tissue impedes effective muscle 
regeneration [89]. Taken together, these results indicate that the earlier initiation of muscle 
regeneration in the injured muscle of MSTN-/- mice compared with the injured muscle of WT 
mice is at least partially due to accelerated removal of muscle debris.  
Because MSTN probably has an inhibitory effect on the chemotaxis of macrophages [71], 
transient increases of MSTN in necrotic myofibers may explain the slower phagocytosis and 
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inflammatory process in the injured muscle of WT mice compare with the injured muscle of 
MSTN-/- mice.  
4.5.2 Repair 
4.5.2.1 Muscle regeneration  
Our results indicate that with the deregulation of MSTN, MSTN-/- mice contain regenerating 
myofibers with larger diameters than exhibited by those found in normal controls 2 weeks after 
laceration. Previous studies suggest that MSTN inhibits myoblast differentiation by the following 
mechanisms: (1) negatively regulating self-renewal and differentiation of satellite cells [92]; (2) 
slowing cell withdrawal from the cell cycle and thereby reducing myoblast differentiation [53]; 
(3) decreasing the expression of members of the basic helix-loop-helix transcription factors (i.e., 
MyoD, Myf5, myogenin) [53, 56] and (4) interfering with the activity of MyoD (its formation of 
Smad3-MyoD associations and its phosphorylation) and thereby decreasing the activity of MyoD 
[53, 56]. Satellite cells are believed to serve as a reservoir of myogenic progenitor cells, 
recruiting myofibers for postnatal growth, repair, and maintenance of skeletal muscle. Satellite 
cells are mitotically quiescent; however, in response to muscle damage, satellite cells are 
activated and reenter the cell cycle to self-renew and differentiate toward a myogenic lineage. 
MSTN is expressed by satellite cells. Interestingly, the intact muscle of MSTN-/- mice contains 
more satellite cells and a higher proportion of activated satellite cells than observed in the intact 
muscle of WT mice [92]. Although a burst of muscle growth occurs in young animals, senescent 
MSTN-/- mice (2 years old) still maintain active muscle regenerative capacity, a fact that 
precludes depletion of the satellite cell pool in MSTN-/- mice [93]. In the same study, at 7 days 
after cardiotoxin-induced tibialis muscle injury, diameters of regenerating myofibers in MSTN-/- 
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mice reach 55% of non-injured muscle in contrast with 36% in WT regenerating muscle [93]. 
This finding suggests increased growth in MSTN-/- regenerating muscle. 
After skeletal muscle injury, quiescent satellite cells are released from the disrupted basal 
lamina and sarcolemma, become activated, and proliferate and differentiate into myogenic cells 
[94]. Muscle regeneration results from fusion of myogenic cells with each other or fusion with 
pre-existing myofibers [95]. MSTN negatively regulates activation of satellite cells by 
upregulating p21, a cyclin-dependent kinase (Cdk) inhibitor. Specifically, MSTN inhibits Cdk2 
protein and thereby prevents satellite cells from progressing from the G1 to the S phase and 
forces the satellite cells to remain in a quiescent state [92]. Compared with WT mice, MSTN-/- 
mice contain significantly higher numbers of both quiescent and activated satellite cells, 
irrespective of the animals’ ages [92, 93]. Myoblasts isolated from MSTN-/- mice proliferate 
faster than myoblasts isolated from WT mice in vitro. Furthermore, compared with the injured 
muscle of WT mice, the injured muscle of MSTN-/- mice contains almost twice as many 
myogenic cells 2 to 5 days after notexin-induced muscle injury [92]. Moreover, the muscle 
regulatory factors MyoD and myogenin are expressed earlier in injured muscle of MSTN-/- mice 
than in that of WT mice [71]. MSTN deficiency may also improve muscle healing by enhancing 
regeneration. Recombinant MSTN inhibits the activation of satellite cells and the chemotactic 
migration of myoblasts and macrophages ex vivo [71]. Accordingly, 2 days after injury MSTN-/- 
mice (compared with WT mice) present with increased cellularity in injured muscle resulting 
from accelerated migration of myogenic cells and macrophages [71]. 
In this study, we found increased expression of MSTN protein in necrotic myofibers at 
early time points after laceration injury. The increased levels of MSTN could modulate the 
activation of satellite cells and their proliferation and differentiation during the early phase of 
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muscle healing. In light of these results, we postulate that the muscle damage in MSTN-/- mice 
leads to the activation of more satellite cells than does muscle damage in WT mice, and the 
activated satellite cells in the MSTN-/- mice differentiate toward the myogenic lineage and fuse 
to form myofibers at higher rates than do satellite cells in WT mice.  
Moreover, it is fair not to attribute enhanced muscle regeneration only to increased 
satellite cell fusion. MSTN inhibits total protein synthesis in C2C12 myoblasts and myotubes, 
and does not affect the rate of protein degradation in myotube in vitro[96]. Welle et al. recently 
reported increase myofibrillar protein synthesis in compared to WT mice [97]. Although 
hypercellularity results from hyperplasia in MSTN-deficient mice, synthesis per myonucleus is 
increased in myostatin-deficient mice [96].   
4.5.2.2 Deposition of ECM 
 
Muscle regeneration and fibrosis are 2 competitive processes that overlap during muscle repair. 
Muscle regeneration spontaneously occurs early in the healing process. However, with the 
accumulation of ECM, some TGF-β1-positive regenerated myofibers become smaller and are 
eventually displaced by mononucleated cells [17]. Numerous reports have shown that wound 
healing requires the transient presence of myofibroblasts that promote wound contraction and 
most of the deposition of ECM, such as fibronectin, collagens I and III, and tenasin. A variety of 
cytokines concentrated at the injured site, including  PDGF, tumor necrosis factor α (TNF-α), 
bFGF, and connective tissue growth factor (CTGF), can exert mitogenic and/or chemotactic 
effects on resident fibroblasts [98]. As a result, fibroblasts populate the wound area, proliferate, 
and produce ECM components that fill the tissue defect and favor normal repair by acting as a 
tissue scaffold. In response to the healing milieu, fibroblasts start to express α-SMA and thus 
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adopt a myofibroblastic phenotype. Myofibroblasts account for most of the cells actively 
synthesizing collagen during tissue repair [99]. Some research suggests that excessive activity of 
myofibroblasts is associated with abnormal accumulation of ECM [78, 79]. In this study we 
found that MSTN stimulated the proliferation of fibroblasts and their myofibroblastic 
differentiation in vitro. Moreover, results of Masson’s Trichrome staining revealed significantly 
less collagenous tissue deposition in the injured muscle of MSTN-/- mice compared with the 
injured muscle of WT mice. These results are consistent with a key characteristic myofibroblasts: 
They produce elevated greater amounts of ECM proteins, particularly collagen, than do other 
fibroblast precursors [100]. McCroskery et al demonstrated reduced scarring in the injured 
tibialis anterior muscles of MSTN-/- mice [71]. Because MSTN induces fibroblasts to 
differentiate into myofibroblasts, it is reasonable to postulate that reduced collagen deposition in 
injured MSTN-/- muscle results from fewer myofibroblasts or myofibroblasts with shorter 
lifespans.  
Researchers have observed that the muscles of mdx mice with MSTN gene knockout 
(MSTN-/-/mdx) contain regenerating myofibers with larger diameters than those of myofibers in 
the muscles of normal mdx mice (MSTN+/+/mdx). It is particularly important to note that these 
MSTN-/-/mdx mice exhibit decreased fibrosis [6]. These results strongly suggest that MSTN 
plays an important role in fibrosis after skeletal muscle injury. In this study we found that, like 
TGF-β1, MSTN activates fibroblasts by stimulating fibroblast proliferation and inducing 
differentiation of fibroblasts into myofibroblasts in vitro. Activin, a member of the TGF-β 
superfamily, can stimulate proliferation of NRK-49F cells, a rat kidney fibroblast cell line, by 
binding to activin receptor II receptor (ActRII) [101]. This result suggests that fibroblasts may 
express activin-related receptors. The purified active dimer of C-terminal MSTN is capable of 
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binding the active type II receptor, ActRIIB, at a high level and ActRIIA at a relatively lower 
level [61]. Follistatin, an antagonist of activin, can bind MSTN and block its binding to ActRIIB 
[61]. Thus, MSTN may stimulate fibroblast proliferation by activating the ActRII pathway. 
Because recombinant MSTN stimulates fibroblast proliferation and myofibroblastic 
differentiation in vitro, the absence of MSTN in an animal may decrease the recruitment of 
fibroblasts and reduce collagenous tissue deposition. This possibility is confirmed by the 
decrease in fibrotic area in MSTN-/- mice 2 weeks after injury, the time when collagenous tissue 
is being actively synthesized. Our in vivo studies revealed that the muscles of MSTN-/- mice 
displayed significantly less fibrotic scar tissue and significantly more hypertrophic regenerating 
myofibers 2 weeks after laceration than did WT controls. These findings are consistent with 
results from previous studies showing that either blocking MSTN or neutralizing TGF-β1 has 
similar beneficial effects on muscle healing after injury [4], and further confirm the strong 
correlation of MSTN expression and fibrosis. Recently, McCroskery et al. reported that there is 
less fibrosis in the notexin-damaged tibialis anterior of MSTN-/- mice 4 weeks after injury than 
in the similarly damaged muscle of WT mice, although the researchers performed no 
quantification of scar formation in that study [71].  
During muscle regeneration, myofibroblasts are primary contributors to the deposition of 
ECM. We found that MSTN induced fibroblasts to proliferate and undergo myofibroblastic 
differentiation. MSTN may also protect myofibroblasts from apoptosis. The reduced amount of 
connective tissue in the regenerated muscle of MSTN-/- mice could also be due to more limited 
fibroblast infiltration or short lifespans of myofibroblasts in the injured site.  
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4.5.3 Remodeling? 
During the remodeling phase, regenerated myofibers and connective tissue undergo maturation. 
Late in the remodeling phase, scar resolution, which involves degradation of collagens and other 
matrix proteins, begins [102]. A variety of collagenases and other metalloproteinases from 
granulocytes, macrophages, and fibrobasts participate in degrading scar tissue and altering its 
composition over months. That process is beyond the scope of this project. However, the 
decrease in the level or activity of matrix metalloproteinases in chronic scarring states may 
partially explain excessive scar tissue size [103]. MSTN may reduce the expression level or 
activity of matrix metalloproteinases or increase the expression of inhibitors of matrix 
metalloproteinases.  
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5.0  THE RELATIONSHIP BETWEEN TGF-BETA1 AND MYOSTATIN 
5.1 ABSTRACT 
TGF-β1 and MSTN both belong to the TGF-β superfamily. These 2 cytokines have similar 
molecular structures, protein processes, and signaling pathways, and share some biologic 
activities. In this study, the potential relationship between TGF-β1 and MSTN was investigated. 
In vitro results showed that TGF-β1 enhanced MSTN expression in C2C12 myoblasts. Also, 
MSTN upregulated TGF-β1 expression in C2C12 myoblasts. In vivo, recombinant MSTN 
protein injection induced TGF-β expression within MSTN-positive myofibers. Moreover, TGF-
β1 and MSTN were transiently co-expressed in myofibers after muscle laceration. Our results 
suggest that TGF-β1 and MSTN are closely related. The balanced expression of these 2 
molecules is important for muscle healing.  
5.2 INTRODUCTION 
TGF-β1 and MSTN are both members of the TGF-β superfamily. Like TGF-β, MSTN is 
synthesized as precursor protein consisting of a signal sequence, a propeptide, and a C-terminal 
region [26]. After proteolytic removal of the signal sequence and propeptide, the C-terminals are 
able to form an active homodimer linked by a disulfide bond. Like TGF-β, MSTN circulates in 
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the blood in its latent form, binding to inhibitory proteins such as its propeptide, follistatin, and 
follistatin-related gene (FLRG) [61, 104-106]. Furthermore, MSTN signals through a TGF-β-like 
signaling pathway that requires phosphorylation of Smad2/3 [58, 59, 63]. Most importantly, 
although TGF-β1 and MSTN each have distinct biologic roles, both of them also inhibit 
myogenic cell proliferation and differentiation [53, 56, 92, 107]. We have demonstrated that, like 
TGF-β1, MSTN may play a role in fibrosis in skeletal muscle. MSTN stimulates the proliferation 
of fibroblasts and the synthesis of fibrotic proteins (e.g., α-SMA and fibronectin (data not 
shown)) in fibroblasts. Whereas TGF-β1 expression strongly correlates with fibrosis in mdx 
mice, lack of MSTN significantly attenuates the severity of fibrosis in MSTN-/-/mdx mice [27]. 
Our in vivo results further showed less fibrosis in MSTN-/- mice than in WT mice after severe 
laceration injury. Taken together, these findings suggest that TGF-β1 and MSTN may interact to 
promote fibrosis in skeletal muscle. The purpose of this study was to perform experiments in 
vitro to determine if MSTN stimulates TGF-β1 expression and vice versa, and in vivo if 
recombinant MSTN injection induces TGF-β1 expression.  
5.3 MATERIALS AND METHODS 
5.3.1 Protein expression and western blot  
C2C12 myoblasts were purchased from the ATCC (Rockville, MD) and were maintained in the 
same conditions as fibroblasts. Mouse C2C12 myoblasts are a well-characterized myogenic cell 
line that is capable of recapitulating myogenesis in vitro. For cell culture methods, see section 
4.3.1. To assess MSTN expression, C2C12 myoblasts were seeded into collagen-coated 6-well 
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plates at a density of 3 x 104 cells per well overnight. Then, cells were grown in low-serum 
medium supplemented with different concentrations of TGF-β1. Medium and growth factor were 
changed every 2 days. Cell lysate was collected for western blot analysis to detect MSTN 
expression in cells. For western blot methods, see section 4.3.3.   
5.3.2 Enzyme-linked immunosorbent assay (ELISA) 
For TGF-β1 ELISA assay, C2C12 myoblasts were seeded into collagen-coated 48-well plates at 
a density of 3000 cells per well and incubated overnight. The next day, the medium was replaced 
with fresh low-serum (2% HS serum) medium to avoid serum interference with TGF-β1. 
Different concentrations of human recombinant MSTN were added, with fresh MSTN added into 
the cell culture every 2 days. Conditioned medium was collected and stored at –80oC until assay.  
A Mouse/Rat/Porcine TGF-β1 immunoassay kit (R&D Systems, Inc. Minneapolis, MN) 
was used to quantitatively measure the TGF-β1 concentrations in cell culture supernates. C2C12 
myoblasts were plated into 48-well plates and exposed to different concentrations of MSTN for 4 
days. Cell supernates were centrifuged to remove cell debris and were stored at –80oC until 
analysis. One hundred microliters of the supernates was activated by HCl and neutralized by 
NaOH. ELISA was performed following the protocol from the manufacturer. Fifty microliters of 
assay diluent RD1-21 and 50 μL of standard, control, or activated samples were mixed in 
duplicate in precoated wells in 96-well plates. After incubation for 2 h at room temperature, the 
solution was removed from the microplate wells and the wells were washed 5 times with wash 
buffer. After the addition of 100 μL of TGF-β1 conjugate to each well, the microplate wells were 
incubated for another 2 h at room temperature on a shaker; the wells then were aspirated/washed 
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as described above. For color development, 100 μL of substrate solution was added into each 
well and incubated for 30 min at room temperature. Color reaction was stopped by the addition 
of stop solution. Quantities of TGF-β1 concentration were determined at 405 nm with a 
microplate ELISA reader. Optical imperfections in the plate were corrected by subtracting 
readings at 570 nm from the reading at 450 nm.  
5.3.3 Animal experiments 
In this study, 9 C57BL/6J mice were used. After administration of anesthesia as described at 
section 4.3.4.1, 400 ng of MSTN in 10 μL of PBS was injected into left GM of each mouse while 
10 μL of PBS alone was injected into the contralateral GMs of the mice. Three Mice injected 
with MSTN were euthanized 4, 10, and 24 hours after injection. GMs were snap frozen and 
cryosectioned. Immunohistochemical staining was performed to detect MSTN and TGF-β1 
expression.      To determine the expression of TGF-β1 and MSTN after injury, muscle sections 
from section 4.3.4.1 after laceration were used for dual immunohistochemistry staining.  
5.3.4 Immunohistochemistry 
To test TGF-β1 and MSTN expression in injured muscle at different times after laceration, 
muscle sections were subjected to TGF-β1 and MSTN immunohistochemical analysis as 
described in section 4.3.4. The sections were fixed in 4% formalin for 5 min, and then were 
washed in PBS twice (10 min per wash). The sections then were blocked with 10% HS for 1 h. 
The primary antibody specific for MSTN (1:100) or TGF-β1 (1:150; Novocastra Laboratories, 
Ltd) was diluted in 2% HS and applied to the muscle sections, which were incubated overnight at 
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4oC. After being washed in PBS 3 times (10 min per wash), the sections were incubated for 1 h 
with the secondary antibody, goat anti-rabbit IgG conjugated with 555 (for anti-MSTN antibody) 
or anti-mouse IgG conjugated with FITC (both diluted 1:200 with 2% HS). Hoechst was used to 
stain nuclei.   
5.4 RESULTS 
5.4.1 In vitro 
The potential interaction between TGF-β1 and MSTN was explored because TGF-β1 and MSTN 
have been demonstrated to share the same signaling pathway [62, 63]. We found that the 
administration of TGF-β1 increased MSTN expression in C2C12 myoblasts. Compared with 
very low-level expression of MSTN in C2C12 myoblasts, MSTN levels in C2C12 myoblasts 
treated with different concentrations of TGF-β1were elevated (Figure 5.1).  
 
 
Figure 5.1 TGF-β1 stimulates myostatin expression in C2C12 myoblasts 
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Interestingly, when C2C12 myoblasts were incubated with different concentrations of 
MSTN for 4 days, ELISA showed MSTN significantly stimulated TGF-β1 secretion by C2C12 
myoblasts in a dose-dependent manner (Figure 5.2). 
 
Figure 5.2 Myostatin increases secretion of TGF-β1 by C2C12 myoblasts 
5.4.2 In vivo 
The injection of MSTN into intact GMs induced TGF-β1 expression in the myofibers 4, 10, and 
24 h after injection. MSTN and TGF-β1 were co-expressed in myofibers at 4 and 10 h. At 24 h, 
MSTN disappeared, and only a few TGF-β1-positive myofibers could be observed (Figure 5.3). 
MSTN detected within the myofibers either resulted from myofiber uptake of exogenous injected 
MSTN or from autocrine expression by myofibers in response to MSTN stimulation. 
We observed co-expression of MSTN and TGF-β1 in necrotic myofibers 1 and 3 days 
after injury (Figure 5.4). By day 5, MSTN were seen within the nuclei of the regenerating 
myofibers, except for in a few MSTN-positive necrotic myofibers, whereas TGF-β1 had 
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migrated into the surrounding ECM. The longer colocalization of MSTN and TGF-β1 expression 
in injured muscle was probably the result of the severe damage to the muscle caused by the 
laceration and the quick clearance of the protein after injection. 
 
Figure  5.3 Myostatin injection induces TGF-β1 expression in the skeletal muscle 
 
 
Figure 5.4 Colocalization of TGF-β1 and myostatin in necrotic myofibers after laceration 
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5.5 DISCUSSION 
Both MSTN and TGF-β1 are members of the TGF-β superfamily. In contrast to the ubiquitous 
expression of TGF-β1, MSTN expression occurs predominantly in skeletal muscle, although low 
levels of MSTN have been detected in cardiac muscle, the mammary glands, and adipose tissue 
[26, 108]. MSTN [55, 56] and TGF-β1 [109]  have inhibitory effects on the myogenic 
differentiation of myoblasts by suppressing the expression of MRFs such as MyoD, Myf5, and 
myogenin. It has been shown that MSTN expression increases with the degree of confluency of 
C2C12 myoblasts cultured in PM, whereas TGF-β1 expression decreases [82]. However, 
expression of MSTN and TGF-β1 follow a similar pattern during the process of C2C12 
differentiation [82]. Both MSTN and TGF-β1 are downregulated transiently within the first 2 
days of differentiation, a process believed to facilitate the initiation of myogenic differentiation. 
After the period of arrested expression, TGF-β1 rapidly returned to and stayed at the original 
high level. Meanwhile, MSTN expression slowly increased and only reached half of the original 
level. These findings suggest that the expression of MSTN and TGF-β1 at certain balanced 
levels regulates the rate of muscle growth [82].  
Our in vitro results show that TGF-β1 increases MSTN expression in the cytoplasm of 
C2C12. These findings are consistent with a recent report that exogenous administration of TGF-
β1 strongly stimulates expression of MSTN [82]. These results were further confirmed by a 
separate experiment in which TGF-β1 failed to enhance MSTN protein expression in C2C12 
myoblasts containing silenced Tβ-RII (Tβ-RII(-))[82]. The silencing of TGF-β receptor II (Tβ-
RII) led to decreases in the expression of MSTN by C2C12 myoblasts. However, during the 
differentiation of C2C12 myoblasts with Tβ-RII(-) , a trend of increasing MSTN expression was 
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still observed. Together with opposite expression trends of TGF-β and MSTN in proliferating 
C2C12 myoblasts [82], it suggests that MSTN is only partially regulated by TGF-β1 [82]. The 
molecular basis of TGF-β1-regulated MSTN expression is that MSTN signals through a TGF-β-
like pathway. There are Smad binding sequences in the 5′ regulatory region of the MSTN gene. 
It is postulated that TGF-β1 binding to Tβ-RII activates Tβ-RI, which results in a complex of 
phosphorylated receptor-regulated Smads (e.g., Smad2/3) and common Smad (i.e., Smad4) that 
translocates into the nucleus and binds to the smad-binding site in the 5′ regulatory region of the 
MSTN gene, thereby activating MSTN gene transcription [82].  
We also found that MSTN stimulates C2C12 myoblasts to secrete TGF-β1 into 
differentiation culture medium in vitro, and that MSTN injection into skeletal muscle caused 
predominant TGF-β1 expression. These results suggest that the relationship between MSTN and 
TGF-β1 is more complicated than simple upregulation of MSTN by TGF-β1.  
Furthermore, TGF-β1 and MSTN colocalize in the necrotic myofibers shortly after 
injury. MSTN is known to negatively regulate chemotaxis of macrophages. Compared with WT 
mice, MSTN-/- mice have demonstrated an accelerated inflammatory response after muscle 
injury [71]. Unlike MSTN, TGF-β1 has been shown to act as a chemoattractant for phagocytes 
and inflammatory cells [110, 111]. This result suggests that TGF-β1 and MSTN probably act 
together to maintain the balance between inhibitory and stimulatory factors in the inflammatory 
response.  
Given the stimulatory effect of TGF-β1 and MSTN on fibroblasts both in vitro and in 
vivo, it was suggested that either MSTN itself is a fibrosis-related factor or that MSTN acts as a 
cofactor of TGF-β1 to promote fibrosis. These possibilities could shed light on the finding that 
MSTN gene knockout not only promotes muscle regeneration but also attenuates the severity of 
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fibrosis in mdx mice [27]. Also, it may help explain why MSTN-/- mice show less fibrosis in the 
injured TA muscle [71] and GM.  
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6.0  THE INHIBITORY EFFECT OF DECORIN ON MYOSTATIN 
6.1 ABSTRACT 
Decorin has been shown to reduce fibrosis in a variety of tissues, including muscle. In our 
previous study, we have shown that MSTN is a stimulator in fibrogenesis. In this study, we 
investigated whether decorin blocks the stimulatory effect of MSTN on fibroblasts and the 
inhibitory effect of MSTN on myoblasts. The results show that decorin blocked MSTN-induced 
fibroblast proliferation and protein expression in fibroblasts and that decorin reversed MSTN-
inhibited myogenic differentiation of myoblasts. Because decorin is the most abundant 
proteoglycan present in the ECM of adult muscle [112], we examined whether decorin 
expression in the injured muscle of MSTN-/- mice differs from that in the injured muscle of 
control WT mice. Our findings indicate that the elevated decorin expression in injured MSTN-/- 
muscle is likely at least partially responsible for the increased muscle healing capacity of the 
skeletal muscle of MSTN-/- mice.  
6.2 INTRODUCTION 
Decorin is an antifibrogenesis reagent due to its inhibitory effect on TGF-β1. Decorin core 
protein is able to bind to TGF-β1, thereby preventing TGF-β1 from binding to its own receptor. 
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It has been shown that administration of decorin reduces fibrosis in different tissues, including 
the liver, lungs, and muscle. It is believed that fibrosis after injury impedes complete 
regeneration. Therefore, the mechanisms by which decorin improves muscle healing deserve 
further investigation. MSTN, a member of the TGF-β superfamily, is almost exclusively 
expressed in skeletal muscle. Like other members of the TGF-β superfamily, MSTN is 
synthesized as a precursor protein consisting of a signal sequence, an N-terminal propeptide 
domain, and a C-terminal domain [26]. Like the TGF-βs, MSTN contains 9 cysteine residues in 
the carboxyl-terminal region that is responsible for the activity of MSTN. After secretion, the 
precursor protein of MSTN is proteolytically processed, and the resulting C-terminal regions are 
capable of forming dimers linked by disulfide bonds [26]. Like TGF-β1, the biologic activities of 
MSTN are regulated by its propeptide [61, 105, 106, 113]. Given the similarities in molecular 
structure, protein process, and propeptide regulation exhibited by TGF-β1 and MSTN, we 
hypothesized that decorin would be able to inhibit MSTN’s biologic activities as it does those of 
TGF-β1.   
6.3 MATERIALS AND METHODS 
6.3.1 Fibroblast proliferation assay 
To examine whether decorin blocks the stimulatory effect of MSTN on fibroblast proliferation, 
PP1 fibroblasts were plated onto collagen-coated 96-well plates. Following overnight 
attachment, normal medium was replaced with serum-free medium containing serum 
replacement (Sigma, St. Louis, MO). Except for the control group, each well was treated with the 
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same concentration of recombinant MSTN (100 ng/mL) and concurrent addition of bovine 
cartilage decorin (Sigma, St. Louis, MO) at increasing concentrations (0–100 μg/mL). Each 
group was run in 6 wells. After 48 hours of incubation, an MTT assay kit was used to measure 
cell proliferation.  
6.3.2 MSTN expression in PP1 fibroblasts 
To examine MSTN expression in fibroblasts, PP1 fibroblasts were seeded into collagen-coated 
6-well plate in normal medium overnight. The second day, the medium was replaced with 
DMEM containing serum replacement with addition of MSTN and/or decorin. Protein samples 
was collected and run western blot as described at section 3.4.3. Polyclonal rabbit anti-MSTN 
antibody ( 1:3000, Chemicon, Temecula, CA)  was use to detect MSTN expression. 
6.3.3 Myogenic differentiation assay of myoblasts 
6.3.3.1 C2C12 myoblast culture with MSTN 
C2C12 myoblasts were used to test the effect of MSTN on myogenic differentiation of 
myoblasts. For the differentiation assay, C2C12 myoblasts were seeded in a 12-well plate at a 
density of 10,000 cells per well. After overnight attachment, C2C12 myoblasts were placed in 
DMEM supplemented with 2% FBS and 1% P/S (differentiation medium) in the presence of 
recombinant MSTN (0-1 μg/mL). Plates were incubated at 37°C in 5% CO2 for 6 days. Fresh 
medium and recombinant MSTN were added every other day.  
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6.3.3.2 C2C12 myoblast culture with MSTN and decorin 
To test whether decorin reverses MSTN’s inhibitory effect on differentiation, C2C12 myoblasts 
were seeded in a 12-well plate at a density of 10,000 cells per well. After overnight incubation, 
medium was replaced with fresh differentiation medium with or without MSTN (1 μg/mL). 
Concomitantly, decorin (0–50 μg/ml) was added to the medium. The cells then were cultured for 
5 days. Fresh differentiation medium, MSTN, and decorin were added every other day. 
6.3.3.3  Immunocytochemistry 
To monitor the myogenic differentiation capacity of myogenic cells after induction of 
differentiation, cells were fixed in cold methanol for 2 min. After being washed in PBS, the cells 
were blocked with 10% HS (Vector Laboratory, Burlingame, CA) for 30 min. The cells then 
were incubated with anti-myosin heavy chain (MyHC) antibody (Sigma, St. Louis, MO) in 2% 
HS overnight. The next day, after being washed 3 more times in PBS (10 min per wash), the 
cells were incubated for 1 h with the secondary antibody, goat anti-mouse IgG conjugated with 
Cy3 (Sigma, St. Louis, MO). Hoechst was used to stain nuclei. For quantification of myotube 
formation, 5 representative fields with myotubes in each wells (n = 3) were photographed. 
6.3.4 Decorin expression in injured skeletal muscles 
To determine decorin expression in injured muscle in both WT and MSTN-\- mice, muscle 
sections from both injured WT and MSTN-/- mice 2 weeks after laceration from scection 4.3.4.2 
were used for decorin immunohistochemistry staining. Polyclonal rabbit anti-decorin antibody to 
the core protein of mouse decorin (LF-113) was from Dr. Larry Fisher (National Institute of 
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Dental Research, Bethesda, MD). Intensity of decorin expression was measured with Northern 
Eclipse software. 
6.4 RESULTS 
6.4.1 In vitro 
6.4.1.1 Decorin inhibits MSTN-stimulated PP1 fibroblast proliferation 
Decorin is a potent antifibrosis agent that acts by neutralizing TGF-β1. Because MSTN is also a 
fibrosis-related member of the TGF-β superfamily, we investigated whether decorin can 
inactivate MSTN. In our study, MSTN (0.1 μg/mL) was shown to induce significant PP1 
fibroblast proliferation. Thus we used the same dose of MSTN to determine if decorin can reduce 
the proliferative influence of MSTN on PP1 fibroblasts. After PP1 fibroblasts had been incubated 
with decorin and MSTN for 48 h, an MTT assay was performed to evaluate the proliferation 
capacity of PP1 fibroblasts treated with both MSTN and various concentrations of decorin. As 
we expected, the concurrent addition of decorin significantly repressed the stimulatory effect of 
MSTN on PP1 fibroblast proliferation (Figure 6.1), a finding that parallels the results reported 
previously [22] indicating that decorin blocks the stimulatory effect of TGF-β on PP1 fibroblasts.  
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 Figure 6.1 Decorin blocks the stimulatory effect of myostatin on PP1 fibroblasts 
6.4.1.2 Decorin inhibits MSTN autocrine expression in PP1 fibroblasts 
We have found MSTN induced autocrine expression in PP1 fibroblasts (Figure 6.2). After 48 h 
incubation, PP1 fibroblasts didn’t express detectable levels of MSTN protein. PP1 fibroblasts 
treated with MSTN showed a marked MSTN level compared to controls.  Although we can not 
rule out the possibility that MSTN protein detected from PP1 fibroblasts could result from the 
fibroblasts’ uptake of exogenous MSTN from the medium, Yamanouchi et al. reported that 
fibroblast is a resource of MSTN [114]. In situ  hybridization analysis revealed MSTN mRNA 
was positive in both myogenic and nonmygenic cells indicated by  immunohistochemical 
staining for desmin and vimentin [114]. Furthermore, skeletal muscle-derived fibroblasts isolated 
from regenerating skeletal muscle expressed MSTN mRNA and crushed muscle extract collected 
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from regenerating skeletal muscle up-regulated mRNA expression in a does-dependent manner 
[114]. However, when we treated PP1 fibroblasts with both MSTN and decorin, MSTN 
expression was reduced to a barely detectable level (Figure 6.2).  If the MSTN protein detected 
in the fibroblasts was exogenous, the reduced MSTN level in fibroblasts treated by MSTN and 
decorin suggests that decorin blocks the uptake of MSTN by fibroblasts. 
 
Figure 6.2 Decorin blocks myostatin autocrine expression in fibroblasts 
6.4.1.3 MSTN inhibits C2C12 myoblast differentiation 
To confirm the inhibitory influence of MSTN on C2C12 myoblast differentiation, we performed 
differentiation experiments in the presence of varying concentrations of MSTN (0–1000 ng/mL). 
As reported before, MSTN is believed to be an inhibitor of myoblast differentiation [53, 55, 56]. 
In contrast to the early differentiation triggered in control cells at 3 days, fusion of MSTN-treated 
C2C12 cells was retarded. At 6 days, many large multinucleated myotubes were present in the 
control culture, but only small myotubes were observed in the cell cultures treated with MSTN (1 
µg/mL) (Figure 6.3). Myotubes were monitored by MyHC immunostaining, and a fusion index 
was calculated by determining the ratio of nuclei in fused myotubes (containing ≥2 nuclei) 
versus the total number of nuclei. A significant concentration-dependent decrease in fusion index 
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was observed in the cultures supplemented with MSTN (Figure 6.4): The myoblasts formed by 
C2C12 cells treated with MSTN contained fewer nuclei. 
 
Figure 6.3 Myostatin inhibits C2C12 myoblast differentiation 
 
Figure 6.4 Myostatin significantly inhibits C2C12 myoblast differentiation in a dose-
dependent manner, as indicated by a fusion index     
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6.4.1.4 Decorin reverses MSTN-inhibited C2C12 myoblast differentiation 
Given the strong inhibition of myoblast differentiation observed after treatment with MSTN at a 
concentration of 1 µg/ml, we used the same concentration to assess whether decorin treatment 
can negate the inhibitory effect of MSTN on myogenic differentiation. Again, 10,000 C2C12 
myoblasts were seeded in each well of a 12-well plate. After overnight incubation, the medium 
was replaced with low-serum medium to initiate myogenic differentiation in the presence of the 
2 recombinant proteins, decorin and MSTN. Myotube formation was monitored by 
immunocytochemistry using the anti-MyHC antibody. We counted the number of MyHC-
positive myotubes (containing ≥2 nuclei) as total number of myotubes; Myotubes containing 3 or 
more nuclei were considered large myotubes. Except for controls, all cultures were 
simultaneously treated with MSTN (1 μg/mL) and increasing concentrations of decorin (0–50 
μg/mL). After incubation for another 5 days, control cells had formed many MyHC-postive 
myotubes, whereas cultures treated with MSTN alone lacked myotubes. More interestingly, 
decorin reversed the inhibitory effect of MSTN on myogenic differentiation in a dose-dependent 
manner (Figure 6.5). Quantification showed that decorin treatment promoted significant C2C12 
myoblast differentiation in the presence of MSTN (Figure 6.6). As shown in Figure 6.7, decorin 
also significantly reversed MSTN’s inhibitory effect on large myotube formation. That is, C2C12 
myoblasts co-incubated with decorin and MSTN were still able to undergo myogenic 
differentiation to a certain extent. Taken together, our results show that decorin antagonized the 
effects of MSTN in all experiments that we performed. Therefore, decorin appears to have a 
similar neutralizing effect on both TGF-β1 and MSTN.  
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Figure 6.5  Decorin reverses the inhibitory effect of myostatin on C2C12 myoblast 
differentiation  
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 Figure 6.6  Decorin significantly reverses myostatin’s inhibition of myotube formation 
 
 
 
Figure 6.7 Decorin significantly reverses myostatin’s inhibition of large myotube formation 
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6.4.2 In vivo 
Moreover, we observed enhanced decorin expression in the regenerated skeletal muscle of 
MSTN-/- mice compared with the regenerated muscle of WT mice (Figure 6.8; Figure 6.9). 
Decorin is a small proteoglycan in ECM, which is not expressed in the sarcolemma. Figure 6.8 
shows stronger decorin staining in the connective tissue between regenerating skeletal muscles in 
MSTN-/- mice than was observed in WT mice. Quantitative analysis by Northern Eclipse 
software demonstrated significantly higher expression of decorin in injured MSTN-/- skeletal 
muscle than in injured WT skeletal muscle 2 weeks after laceration (Figure 6.9). 
 
 
Figure 6.8 Compared with WT injured muscle, MSTN-/- injured muscle shows elevated 
expression of decorin (red fluorescence) 2 weeks after laceration 
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 Figure 6.9 Decorin expression is significantly increased in MSTN-/- regenerating muscle 
6.5 DISCUSSION 
To further characterize the MSTN molecule, we investigated whether decorin, a potent anti-
fibrosis agent, can neutralize the effects of MSTN. Decorin is a natural inhibitor of TGF-β1 and 
is used as an antifibrotic agent because of its ability to bind with and neutralize TGF-β1 [21, 22, 
37, 64]. Decorin has been proven to improve muscle healing histologically and physiologically 
by increasing muscle regeneration and decreasing fibrosis [21, 22], effects accredited primarily 
to decorin’s ability to neutralize TGF-β1. However, we found that decorin also exerts its 
antifibrotic effect partially by regulating MSTN activity in muscle. We demonstrated that 
decorin effectively blocked the effects of MSTN on both fibroblasts and myoblasts. Decorin 
reduced the stimulating effects of MSTN on fibroblasts and the effect of MSTN expression on 
fibroblasts. Moreover, decorin counteracted the inhibitory effect of MSTN on myoblast 
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differentiation. Decorin binds to TGF-β1 because the core protein of decorin contains 2 binding 
sites for TGF-β1. However, identification of the underlying mechanism by which decorin blocks 
the biologic activity of TGF-β1 will require further investigation. The first possibility is that 
decorin directly binds to MSTN to inhibit it action. Alternatively, decorin may regulate MSTN 
by influencing another intermediate molecule. Follistatin, an antagonist of MSTN, is a possible 
candidate. Follistatin blocks the binding of MSTN to ActRIIB. Our unpublished data show that 
decorin stimulates the expression of follistatin in C2C12 myoblasts and that follistatin can also 
stimulate C2C12 myoblast differentiation. Third, decorin may upregulate the level of MRFs in 
C2C12 myoblasts through a signal transduction pathway that does not involve MSTN. MSTN 
has been known to inhibit myoblast differentiation by down-regulating MRFs [53, 56]. In 
contrast, our unpublished data also show that decorin stimulates myoblast differentiation by 
enhancing MRFs including MyoD, Myf-5, and myogenin.  
Our in vivo results show that the expression of decorin in injured muscle is related to 
MSTN. When compared with injured WT muscle a week after GM laceration, injured MSTN-/- 
muscle showed elevated expression of decorin protein in the ECM between regenerated 
myofibers. Prior experiments have demonstrated increased amounts of decorin mRNA in 
regenerating MSTN-/- TA muscle [71]. We have shown that MSTN strongly stimulates the 
proliferation and myofibroblastic differentiation of fibroblasts. Myofibroblasts are the cells that 
play the largest role in actively synthesizing collagen during tissue repair [99], and the excessive 
activity of myofibroblasts can lead to abnormal accumulation of ECM [78, 79]. Moreover, TGF-
β1 has been proven to be a strong inducer of myofibroblastic differentiation of fibroblasts both in 
vitro and in vivo [18, 19]. In MSTN-/- mice, the absence of MSTN and the presence of high 
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levels of endogenous decorin that neutralizes TGF-β1 (Figure 6.8, Figure 6.9) may reduce 
myofibroblast recruitment to injured muscle and thereby decreases the deposition of ECM. 
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7.0  SUMMARY AND FUTURE DIRECTIONS 
In summary, these studies have shown that MSTN is a stimulator of fibrosis in injured muscle. 
The lack of MSTN greatly improves muscle healing through the enhancement of regeneration 
and inhibition of fibrosis. Our results also reveal that TGF-β1 expression correlates closely with 
MSTN expression. MSTN stimulates TGF-β1 expression in C2C12 myoblasts. And TGF-β1 also 
upregulates MSTN expression in C2C12 myoblasts. Interestingly, we also found transient 
elevated coexpression of TGF-β1 and MSTN in necrotic myofibers after GM laceration. Finally, 
this study shows that decorin, an antifibrosis agent, is capable of blocking the effects of MSTN 
on fibroblasts and myoblasts in vitro, and that the lack of MSTN leads to elevated decorin 
expression in injured skeletal muscle in vivo. 
The findings of this thesis indicate that, like TGF-β1, MSTN is a fibrosis stimulator in 
muscle. Learning about MSTN’s role in fibrosis and its interactions with TGF-β1 and decorin 
will enable us to better understand the mechanisms involved in skeletal muscle fibrosis. During 
skeletal muscle healing, TGF-β1, MSTN, and decorin are strongly related. First, there appears to 
be a loop connecting TGF-β1 and MSTN.  Second, decorin inhibits the activity of both TGF-β1 
and MSTN. Third, MSTN deficiency results in elevated decorin expression in injured skeletal 
muscle. Our results suggest that MSTN could be a pharmacologic target for treating injured and 
diseased muscle by reducing fibrosis and enhancing muscle regeneration. 
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Future studies should examine the effect of MSTN on the production of ECM 
components by fibroblasts, including the production of fibronectin and collagen type I and type 
III. Our studies have shown that MSTN induces fibroblasts to differentiate into myofibroblasts. 
Myofibroblasts produce greater amounts of ECM components, particularly collagen, than do 
fibroblasts [100]. We also will look into whether MSTN prevents fibroblasts from programmed 
apoptosis. In addition, we will investigate whether MSTN is a TGF-β1 downstream target. The 
effects of TGF-β1 on MSTN-/- fibroblasts and myoblasts will be examined. Recombinant TGF-
β1 will be injected into intact MSTN-/- muscle and WT muscle to examine whether TGF-β1 is 
able to induce fibrosis in MSTN-/- mice as it does in normal mice. Finally, the mechanism by 
which decorin blocks MSTN will be examined. Co-immunoprecipitation will be used to test 
whether decorin directly binds to MSTN. If not, decorin and anti-follistatin antibodies will be 
used to co-stimulate C2C12 myoblasts. The finding that anti-follistatin antibody can block 
decorin-induced myogenic differentiation would suggest that decorin indirectly stimulates 
C2C12 differentation mediated by follistatin and that elevated follistatin expression blocks 
MSTN activity.  
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APPENDIX A 
 
DIAMETER ANALYSIS OF REGENERATED MYOFIBERS USING NORTHERN 
ECLIPSE 
A.1 PHOTOGRAPH FOR SECTIONS WITH IMMUNOHISTOCHEMICAL STAIN 
1. Open Northern Eclipse software. 
2. Go to View to select User Window  opening “merge window” 
1) to select colors from “merge window” checking “green” (basal lamina) 
and “blue” (nuclei) box 
2) to chose loop 
3. Select 10x objective lens from fluorescence microscope, focusing and choosing green and 
blue filter subsequently to take merged image (green and blue) 
A.2 ANALYSIS OF REGENERATED MYOFIBER DIAMETER 
1. Go to View to select View Options 
1) Bin (new bin with limited condition: Check “Include these  
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objects” to check new bin, uncheck Default) 
2) Data: Chose right parameters such as “object Count”, “Minimum axis   
diameter” 
2.    Go to Process to choose Conversions to convert image to 8 bit grayscale 
3. * Threshold (Monochrome threshold for 8 bit gray image) 
4.   Go to Measure > Selection Tool to select the area that you want to measure  
5.   Go to View > Data to set “Objects partially inside selection” are “Excluded from selection” 
6.   Optimize condition using New Bin, based on value of measurement.  
7.   View> View Options > Selection  to set Object Marker as yellow dot 
8.   Click on Measure button in Toolbar 
9.   LOG to DDE to export data to Excel spreadsheet 
 
 
Appendix Figure A. 1 Collagen IV immunohistochemistry stain (green) for basal lamina of 
regenerated myofibers (A); Image threshold in 8 bit grey (B) using Northern Eclipse 
software. 
 
 68 
 
Appendix Figure A. 2 Measurement of minimal diameter of regenerated myofibers. Yellow 
dots in the center of myofiber mean the selected myofibers 
Note: 3* the function in this application is used to distinguish the basal lamina of 
myofibers from background. The value of intensity corresponding to the grayness varies from 0 
to 255. When we alter the values, the selected pixels (basal lamina) are shown in red/white, 
while unselected pixels (background) are indicated in cyan/black. 
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APPENDIX B 
PROCEDURES FOR QUANTIZATION OF FIBROSIS FORMATION USING 
NORTHERN ECLIPSE 
Images of injured muscle stained with Masson’s Trichrome stain were photographed with a 
microscope digital camera system using Qcapture software.  
B.1 TAKING BRIGHTFIELD IMAGE AND MASSON'S TRICHROM STAINING 
1. Move the beam under camera to the middle position (which should be  
     moved to the left side for fluorescence picture). 
2. Open Qcapture software 
3. Chose a blank area from slide for white balance 
4. Move slide to find area of interest 
5. Go Acquire and open Living Preview 
6. Use Camera Setting in Acquire to adjust color of picture 
7. Use Snap in Acquire to take picture 
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       Notes: Images of entire cross-sectional muscles were taken under 2x objective lens to so that 
entire muscle section was included.  
B.2 ANALYSIS OF FIBROSIS FORMATION USING NORTHERN ECLIPSE 
1. Open Northern Eclipse 
2. Open your file and use Zoom to adjust size of image (Typically, 50% of image is chosen) 
3. Go Threshold  (color (24 bit) thresholding) to change RGB model to HSV Model (Hue, 
Saturation, Value). The muscle fibers turn to be grey, while the collagenous tissue remains blue. 
And then adjust Hue, Saturation, Value separately so that the collagenous tissue area is 
identical to that in original image (Appendix Figure B.1A).   
5. Go to Measure, Selection Tool , and then choose Trace Tool to draw a line along the edge of 
the muscle cross section. Measurement area is cut by selection, meaning that only area selected 
was measured (Appendix figure B.2) 
6. Use Square tool to select bands of interest 
7. Click on Measure button in Toolbar.  
8. LOG to DDE to export data to Excel spreadsheet 
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 Appendix Figure B. 1 Image of injured muscle cross section (A), same image in HSV model 
 
 
Appendix Figure B. 2 Measurement of scar tissue area (9.3426%) 
Note:  
Threshold is used to distinguish targeted objects from the rest of image by specifying 
range(s) of values such as hue, saturation, brightness. 
 72 
HSV is a distinct color space from RGB (red, green, blue), which is non-linear 
transformation of RGB. Compared to RGV, HSV is more representative for the way 
that humans perceive color.  
Hue refers to the color type arranging from red through the yellows, green, blues, and 
violets: 
? Ranges from 0-360 (but normalized to 0-359 in Northern Eclipse) 
• Saturation indicates the vibrancy of the color: 
? Ranges from 0-100% (but normalized to 0-255 in Northern Eclipse) 
? The saturation of a color is correlated to the “grayness”. When the 
saturation of a color is low, correspondingly, the faded color will appear as 
a result of low grayness. This function is use to define desaturation as the 
qualitative inverse of saturation. 
• Value depicts the brightness of color: 
? Ranges from 0-100% (but normalized to 0-255 in Northern Eclipse) 
 
 
Appendix Figure B. 3 HSV color space as a color wheel 
Http://en.wikipedia.org/wili/HSV_color_space
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As shown in Appendix Figure B.3 the hue is illustrated by a circular region; Saturation 
and value are stood for by a triangle region with a vertical axis indicating saturation and 
horizontal axis representing value. When we do threshold, we began with selecting the hue 
(color) from the circular region, then pick the optimal saturation and value from the triangular 
area. The resultant result is shown in appendix Figure B. 1B. 
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